DB09145

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2012
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
gptkbp:ATCCode B01AF02
gptkbp:availableOn tablet form
gptkbp:bioavailability 50%
gptkbp:brand gptkb:Eliquis
gptkbp:CASNumber 503612-47-3
gptkbp:color yellow
gptkbp:contraindication active pathological bleeding
severe hepatic impairment
gptkbp:drugClass gptkb:anticoagulant
gptkbp:eliminationHalfLife ~12 hours
gptkbp:excretion urine
feces
gptkbp:hasBoxedWarning spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
gptkbp:hasInChIKey SLQNJXNNYZZBOW-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C25H25N5O4
gptkbp:hasPatentExpiry 2026 (US)
gptkbp:hasPharmacodynamics reduces thrombin generation and clot formation
gptkbp:hasPharmacokinetics peak plasma concentration in 3-4 hours
gptkbp:hasReversalAgent gptkb:andexanet_alfa
gptkbp:hasSMILES CC1=CC=CC=C1N2C=NC3=C2N=C(NC3=O)C4=CC=CC=C4C(=O)N5CCOCC5C(=O)O
gptkbp:hasUNII 3Z9Y7UWC1V
https://www.w3.org/2000/01/rdf-schema#label DB09145
gptkbp:indication Treatment and prevention of deep vein thrombosis
Treatment and prevention of pulmonary embolism
Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
gptkbp:legalStatus prescription only
gptkbp:manufacturer gptkb:Pfizer
gptkb:Bristol-Myers_Squibb
gptkbp:mechanismOfAction gptkb:Factor_Xa_inhibitor
gptkbp:metabolism liver (CYP3A4, CYP3A5, CYP1A2, CYP2C8, CYP2C9, CYP2J2)
gptkbp:molecularWeight 459.5 g/mol
gptkbp:name Apixaban
gptkbp:pregnancyCategory B (US)
gptkbp:proteinBinding 87%
gptkbp:PubChem_CID gptkb:DB09145
10182969
8356462
CHEMBL1940625
D09714
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:anemia
nausea
bleeding
gptkbp:synonym BMS-562247-01
gptkbp:target gptkb:Factor_Xa
gptkbp:bfsParent gptkb:UHOVQNZJYSORNB-UHFFFAOYSA-N
gptkbp:bfsLayer 7